Adjusted One-Year Mortality Similar for On-, Off-Label TAVR

Share this content:
Adjusted One-Year Mortality Similar for On-, Off-Label TAVR
Adjusted One-Year Mortality Similar for On-, Off-Label TAVR

WEDNESDAY, June 21, 2017 (HealthDay News) -- Adjusted one-year mortality is similar for individuals undergoing transcatheter aortic valve replacement (TAVR) for on-label or off-label indications, according to a study published online June 21 in JAMA Cardiology.

Ravi S. Hira, M.D., from the University of Washington in Seattle, and colleagues examined patterns and adverse outcomes of off-label use of TAVR, defined as TAVR in patients with known bicuspid valve, moderate aortic stenosis, severe mitral regurgitation, severe aortic regurgitation, or subaortic stenosis, in U.S. clinical practice.

Off-label TAVR was used in 2,272 (9.5 percent) of the 23,847 patients in the study. The researchers found that patients receiving off-label TAVR had higher in-hospital mortality (6.3 versus 4.7 percent; P < 0.001), 30-day mortality (8.5 versus 6.1 percent; P < 0.001), and one-year mortality (25.6 versus 22.1 percent; P = 0.001), compared to those receiving on-label TAVR. The off-label group had higher adjusted 30-day mortality (hazard ratio, 1.27; 95 percent confidence interval, 1.04 to 1.55; P = 0.02), while adjusted one-year mortality was similar between the groups (hazard ratio, 1.11; 95 percent confidence interval, 0.98 to 1.25; P = 0.11). Per hospital, the median rate of off-label TAVR use was 6.8 percent, with increased 30-day adverse cardiovascular events for hospitals in the highest tertile of off-label use versus the lowest tertile.

"These results reinforce the need for additional research on the efficacy of off-label TAVR use," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial 1 (subscription or payment may be required)
Editorial 2 (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Mortality Estimates Favor Annual Mammography From Age 40

Mortality Estimates Favor Annual Mammography From Age 40

Researchers estimate thousands of U.S. lives would be saved each year if mammograms started at age 40

Anti-Vaccine Info in Pregnancy May Delay Infant Immunization

Anti-Vaccine Info in Pregnancy May Delay Infant Immunization

Even if pregnant women later hear better info from doctors, they may still wait on vaccines

Hours Worked Impacted by Kids for Female, Not Male Doctors

Hours Worked Impacted by Kids for Female, Not ...

Findings from a national sample of dual-physician couples

is free, fast, and customized just for you!

Already a member?

Sign In Now »